| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE | 39 |
| 1 | METHOTREXATE SODIUM | 39 |
| 2 | PREDNISONE | 39 |
| 3 | ADALIMUMAB | 24 |
| 4 | CYTARABINE | 22 |
| 5 | CYCLOPHOSPHAMIDE | 21 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 21 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 21 |
| 8 | RITUXIMAB | 21 |
| 9 | SIMVASTATIN | 20 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FEBUXOSTAT TABLETS 40 MG | 14 | 0.0013 |
| 1 | IBRITUMOMAB TIUXETAN | 2 | 0.0013 |
| 2 | PURIXAN | 1 | 0.0013 |
| 3 | CARMUSTINE | 6 | 0.0013 |
| 4 | AMPHOTERICIN B LIPOSOME | 3 | 0.0013 |
| 5 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 5 | 0.0011 |
| 6 | GEMTUZUMAB OZOGAMICIN | 4 | 0.0011 |
| 7 | MARALIXIBAT CHLORIDE | 1 | 0.0010 |
| 8 | VANCOMYCIN HYDROCHLORIDE | 8 | 0.0010 |
| 9 | PROCHLORPERAZINE EDISYLATE | 1 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 74 |
| 1 | Folate Analog Metabolic Inhibitor [EPC] | 40 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 38 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 32 |
| 4 | Benzodiazepine [EPC] | 26 |
| 5 | Alkylating Drug [EPC] | 25 |
| 6 | HMG-CoA Reductase Inhibitor [EPC] | 23 |
| 7 | Proton Pump Inhibitor [EPC] | 22 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 21 |
| 9 | Platinum-based Drug [EPC] | 21 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD33-directed Immunoconjugate [EPC] | 4 | 0.0011 |
| 1 | Interferon gamma [EPC] | 1 | 0.0007 |
| 2 | CD19-directed Chimeric Antigen Receptor [EPC] | 7 | 0.0007 |
| 3 | Lipid-based Polyene Antifungal [EPC] | 7 | 0.0005 |
| 4 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 9 | 0.0004 |
| 5 | Echinocandin Antifungal [EPC] | 3 | 0.0004 |
| 6 | Plasma Volume Expander [EPC] | 1 | 0.0003 |
| 7 | Rifamycin Antimycobacterial [EPC] | 1 | 0.0003 |
| 8 | Antimetabolite Immunosuppressant [EPC] | 6 | 0.0003 |
| 9 | Polyene Antifungal [EPC] | 10 | 0.0002 |